STERIS plc (S1TE34) Fair Value & Analysis
Healthcare · BR · Market cap R$102B
Fair value as of: Jul 16, 2026
From 24 valuation models · updated 7 days ago
Fair value updated Jul 16, 2026, revised from R$8.02 to R$8.03 (+0.1%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range R$52.02 – R$64.86 · fair‑value band R$5.04 – R$10.03 · the R$52.14 price screens above the R$8.03 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
STERIS plc (S1TE34) currently trades at R$52.14, while our model-based Fair Value estimate is R$8.03, implying the stock looks roughly 84.6% overvalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, STERIS plc generated revenue of R$5.9B at a net margin of 13.2%. Revenue grew 7.3% year over year. It earns a return on equity of 11.4%. Net debt stands at R$1.5B. Fundamentals as of Jul 16, 2026
Our scenario range runs from R$5.04 (bear case) to R$10.03 (bull case); at R$52.14, the current price sits above that range. The share trades about 20% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -39% fair-value upside, at -85%, S1TE34 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
STERIS plc reported revenue of R$5.9B in FY2026 versus R$4.2B in FY2022, a compound +8.9%/yr. Reported net income was R$782M in FY2026, compounding +33.8%/yr from FY2022.
Is S1TE34 fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $87.83 | $78.63 | -10% |
| Stryker Corporation SYK | $304.69 | $186.28 | -39% |
| Medtronic plc MDTC34 | R$203.91 | R$27.47 | -87% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EWL | €74.82 | €32.56 | -56% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| DexCom, Inc DXCM | $72.59 | $39.33 | -46% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥144.39 | ¥105.08 | -27% |
| Zimmer Biomet Holdings Z1BH34 | R$119.88 | R$85.65 | -29% |
| Shanghai United Imaging Healthcare Co 688271 | ¥112.98 | ¥56.52 | -50% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is STERIS plc (S1TE34) undervalued?
What is the fair value of S1TE34?
What is the quality score of S1TE34?
What is the revenue of STERIS plc (S1TE34)?
What is the net profit margin of S1TE34?
Does STERIS plc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full STERIS plc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.